Does bivalirudin-based anticoagulation improve safety and cost-effectiveness compared to heparin-based anticoagulation in pediatric ECMO patients?
Bivalirudin may be a safe and cost-effective alternative to heparin for anticoagulation in pediatric ECMO, though prospective RCTs are needed to confirm outcomes.
Bivalirudin may be a safe, cost-effective alternative to heparin in achieving anticoagulation in pediatric ECMO patients. Prospective multicenter studies and randomized control trials with standard anticoagulation targets are needed to accurately compare outcomes associated with heparin versus bivalirudin in pediatric ECMO patients.
Valdes et al. (Tue,) studied this question.